Related Experiment Videos
[Antitumor spectra of ranimustine against various human tumors]
S Fujimoto1, H Tokita, K Nitta
1Division of Chemotherapy, Chiba Cancer Center Research Institute, Japan.
Abstract:
Ranimustine (MCNU) has been shown to exhibit high antitumor activity and broad antitumor spectra against various experimental tumors. These effects were comparable to those of nimustine (ACNU). However, clinical applications of ACNU are indicated to various types of malignancies including solid tumors, while those of MCNU are almost limited to hematological ones. Therefore, the antitumor activity of MCNU was examined against 55 specimens from 15 types of solid tumors and compared with those of ACNU and 8 other drugs. Drug sensitivity was examined by a morphological method measuring the proportion of degenerative changes in the nucleus of drug-treated and untreated tumor cells. MCNU showed antitumor activities (measured by karyorrhexis) against adenocarcinoma of the lung, squamous cell carcinoma of the lung, renal cell carcinoma, bladder tumor, ovarian cancer and brain tumor. In addition, MCNU and ACNU showed a similar positive rate (15-16%) in this experiment and this was the highest among all drugs examined. Although MCNU and ACNU showed similar antitumor spectra, a clear difference was observed when the antitumor activities of both drugs were compared in each identical specimen. These results clearly suggest that MCNU is worthy of clinical study to examine the antitumor activity against various solid tumors.
Insights
Ranimustine (MCNU) shows significant antitumor activity against various solid tumors, comparable to nimustine (ACNU). These findings support further clinical investigation of MCNU for solid tumor treatment.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Ranimustine (MCNU) demonstrates potent antitumor activity and broad spectra against experimental tumors, similar to nimustine (ACNU).
- Clinical use of ACNU encompasses various malignancies, including solid tumors, whereas MCNU is primarily used for hematological cancers.
- A need exists to evaluate MCNU's efficacy against solid tumors.
Purpose of the Study:
- To assess the antitumor activity of MCNU against a range of solid tumor types.
- To compare the efficacy of MCNU with ACNU and eight other anticancer drugs.
- To determine the potential of MCNU for clinical application in solid tumor treatment.
Main Methods:
- Evaluated drug sensitivity using a morphological method to quantify nuclear degenerative changes (karyorrhexis) in tumor cells.
- Tested MCNU against 55 specimens from 15 distinct types of solid tumors.
- Compared MCNU's activity with ACNU and eight other reference drugs.
Main Results:
- MCNU exhibited antitumor activity against lung adenocarcinoma, lung squamous cell carcinoma, renal cell carcinoma, bladder tumors, ovarian cancer, and brain tumors.
- Both MCNU and ACNU demonstrated the highest positive response rate (15-16%) among all tested drugs.
- While MCNU and ACNU shared similar antitumor spectra, individual specimen comparisons revealed distinct activity profiles.
Conclusions:
- MCNU displays significant antitumor activity against several types of solid tumors.
- MCNU's efficacy against solid tumors warrants further clinical investigation.
- MCNU represents a promising therapeutic candidate for solid malignancies.